MX2022014111A - Metodos para el aislamiento de linfocitos t gamma delta. - Google Patents
Metodos para el aislamiento de linfocitos t gamma delta.Info
- Publication number
- MX2022014111A MX2022014111A MX2022014111A MX2022014111A MX2022014111A MX 2022014111 A MX2022014111 A MX 2022014111A MX 2022014111 A MX2022014111 A MX 2022014111A MX 2022014111 A MX2022014111 A MX 2022014111A MX 2022014111 A MX2022014111 A MX 2022014111A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- methods
- haematopoietic
- tissue
- gamma delta
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000003394 haemopoietic effect Effects 0.000 abstract 3
- 210000004698 lymphocyte Anatomy 0.000 abstract 3
- 238000002659 cell therapy Methods 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006989.4A GB202006989D0 (en) | 2020-05-12 | 2020-05-12 | Methods for isolating gamma delta t cells |
| PCT/GB2021/051144 WO2021229226A1 (en) | 2020-05-12 | 2021-05-12 | Methods for isolating gamma delta t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014111A true MX2022014111A (es) | 2022-12-08 |
Family
ID=71134832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014111A MX2022014111A (es) | 2020-05-12 | 2021-05-12 | Metodos para el aislamiento de linfocitos t gamma delta. |
Country Status (13)
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| UA123821C2 (uk) | 2014-06-11 | 2021-06-09 | Полібіосепт Гмбх | Композиція для експансії лімфоцитів in vitro |
| KR20240063197A (ko) * | 2015-06-09 | 2024-05-09 | 감마델타 테라퓨틱스 엘티디 | Tcr 감마 델타 양성 t 세포의 생산 방법 |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| CN108473958A (zh) * | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| JP7557367B2 (ja) * | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 細針吸引及び小生検からのtil拡大培養 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
-
2020
- 2020-05-12 GB GBGB2006989.4A patent/GB202006989D0/en not_active Ceased
-
2021
- 2021-05-12 MX MX2022014111A patent/MX2022014111A/es unknown
- 2021-05-12 CN CN202511225493.3A patent/CN121294340A/zh active Pending
- 2021-05-12 WO PCT/GB2021/051144 patent/WO2021229226A1/en not_active Ceased
- 2021-05-12 CN CN202180035561.3A patent/CN115667501B/zh active Active
- 2021-05-12 CA CA3183145A patent/CA3183145A1/en active Pending
- 2021-05-12 BR BR112022022939A patent/BR112022022939A2/pt unknown
- 2021-05-12 AU AU2021271222A patent/AU2021271222A1/en active Pending
- 2021-05-12 EP EP21727525.4A patent/EP4150055A1/en active Pending
- 2021-05-12 KR KR1020227041283A patent/KR20230010209A/ko active Pending
- 2021-05-12 IL IL298000A patent/IL298000A/en unknown
- 2021-05-12 US US17/998,766 patent/US20230227777A1/en active Pending
- 2021-05-12 JP JP2022568961A patent/JP2023525345A/ja active Pending
-
2022
- 2022-12-07 CO CONC2022/0017768A patent/CO2022017768A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667501B (zh) | 2025-09-16 |
| KR20230010209A (ko) | 2023-01-18 |
| CO2022017768A2 (es) | 2023-04-17 |
| IL298000A (en) | 2023-01-01 |
| GB202006989D0 (en) | 2020-06-24 |
| US20230227777A1 (en) | 2023-07-20 |
| JP2023525345A (ja) | 2023-06-15 |
| AU2021271222A1 (en) | 2023-01-05 |
| CN121294340A (zh) | 2026-01-09 |
| EP4150055A1 (en) | 2023-03-22 |
| BR112022022939A2 (pt) | 2022-12-13 |
| CA3183145A1 (en) | 2021-11-18 |
| WO2021229226A1 (en) | 2021-11-18 |
| CN115667501A (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luyckx et al. | G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells | |
| Magatti et al. | Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities | |
| Béziat et al. | CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation | |
| Vacca et al. | Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression | |
| Najar et al. | Characterization and functionality of the CD200–CD200R system during mesenchymal stromal cell interactions with T-lymphocytes | |
| Ruggeri et al. | Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. | |
| Norris et al. | Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Vα24-JαQ and γδ T cell receptor bearing cells | |
| Alsuliman et al. | A robust, good manufacturing practice–compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy | |
| Cao et al. | Ex vivo expanded human CD4+ CD25+ Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD) | |
| Nikiforow et al. | A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation | |
| EP2014767A1 (en) | T cell immunomodulation by placenta cell preparations | |
| Unsworth et al. | OMIP‐032: two multi‐color immunophenotyping panels for assessing the innate and adaptive immune cells in the mouse mammary gland | |
| AU2003903896A0 (en) | Skin regeneration system | |
| Pozzi et al. | Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation | |
| Killig et al. | Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation | |
| Stenström et al. | Surface receptors identify mouse NK1. 1+ T cell subsets distinguished by function and T cell receptor type | |
| Nguyen et al. | Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation | |
| Uemura et al. | Role of human non-invariant NKT lymphocytes in the maintenance of type 2 T helper environment during pregnancy | |
| Trujillo-Ocampo et al. | Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease | |
| Zeng et al. | B7-1 and B7-2 differentially control peripheral homeostasis of CD4+ CD25+ Foxp3+ regulatory T cells | |
| Stabile et al. | Reconstitution of multifunctional CD56lowCD16low natural killer cell subset in children with acute leukemia given α/β T cell-depleted HLA-haploidentical haematopoietic stem cell transplantation | |
| Shirshev et al. | Roles of leptin and ghrelin in the regulation of the phenotype and cytokine production by NK cells from peripheral blood | |
| PH12021550950A1 (en) | Method for culturing cord blood-derived natural killer cells using transformed t cells | |
| Cao et al. | Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion | |
| Schneiders et al. | Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α |